OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL

OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL

Abstract: Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, 4-1BB chimeric antigen receptor (CAR) T-cell product approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We present the OUTREACH primary analysis, evaluating the safety and efficacy of outpatient monitori...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuliya Linhares, Cesar O. Freytes, Mohamad Cherry, Carlos Bachier, Michael Maris, Daanish Hoda, Juan C. Varela, Courtney Bellomo, Scott Cross, James Essell, Suzanne Fanning, Howard Terebelo, Habte Yimer, Jay Courtright, Jeff P. Sharman, Ana Kostic, Min Vedal, Ken Ogasawara, Ariel Avilion, Ricardo Espinola, Brenda Yuan, Bassam Mattar
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952924005718
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2473952924005718

Similar Items